Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’
Recent Approval For Revance Brand Encourages Viatris On Botox
Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.
